This independent educational activity has been supported by Pierre Fabre Laboratories; where the position and discussions may not represent the policies or position of Pierre Fabre or EMJ. The content has been developed independently by EMJ and is intended for healthcare professionals only (except those within UK & ROI). Considering the nature of our discussion, please always consult your local Summary of Product Characteristics before making any prescription decisions.
Recorded live from Barcelona, Spain, during the 2024 European Society for Medical Oncology (ESMO) Congress, watch Egbert Smit discuss the latest advancements in treatment for BRAFV600-mutant metastatic non-small cell lung cancer (NSCLC). Also, hear from Axel Hauschild and Teresa Amaral as they provide an in-depth overview of the latest insights on targeted therapies for metastatic melanoma.
Speakers:
Egbert Smit1
Axel Hauschild2
Teresa Amaral3
1. Professor of Pulmonary Medicine (Pulmonary Oncology), and Head of the Department of Pulmonary Diseases, Leiden University Medical Centre (LUMC), and Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
2. Professor of Dermatology, University of Kiel, and Head of the Skin Cancer Trial Centre, University Hospital Schleswig-Holstein, Kiel,Β Germany
3. Consultant Medical Oncology and Head of Translational Research, Department of Dermatology, Skin Cancer Clinical Trials Centre, University Hospital and Faculty of Medicine, University of TΓΌbingen, Germany
Moderator:
Hannah Moir4,5
